Clinical trial

Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

NCT00784524

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2008-09-01

PhasePHASE2

Study timeline

Study start (unknown)2008-09-01Date precision: month

Registry last updated2019-06-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

allogeneic large multivalent immunogen breast cancer vaccineBIOLOGICAL

aldesleukinBIOLOGICAL

Sponsors & collaborators

Masonic Cancer Center, University of Minnesotalead sponsor

Mapped research locations

MinneapolisMinnesota, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00784524 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.